Reanalyses of randomized clinical trial data

JAMA - Journal of the American Medical Association

Volumn 312, Issue 10, 2014, Pages 1024-1032

  Ebrahim, Shanil ^a,b,c   Sohani, Zahra N ^b,d   Montoya, Luis ^e   Agarwal, Arnav ^d   Thorlund, Kristian ^a,b   Mills, Edward J ^a,b,f   Ioannidis, John P A ^a,g  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

^g STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; HEMOGLOBIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ARTERIAL WALL THICKNESS; ARTICLE; CARDIAC GRAFT REJECTION; DATA ANALYSIS; DRUG EFFICACY; EFFECT SIZE; HEALTH CARE DELIVERY; HEART TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBINOPATHY; HOLTER MONITORING; HUMAN; INFORMATION PROCESSING; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDLINE; OUTCOME ASSESSMENT; PATIENT SELECTION; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; VALIDATION PROCESS; REVIEW; STATISTICAL ANALYSIS;

DATA INTERPRETATION, STATISTICAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84907014634     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.9646     Document Type: Article

References (44)

1. Sharing public health data: necessary and now. Lancet. 2010;375(9730):1940.
2. Pisani E, AbouZahr C. Sharing health data: good intentions are not enough. Bull World Health Organ. 2010;88(6):462-466.
3. Samet JM. Data: to share or not to share? Epidemiology. 2009;20(2):172-174.
4. Doshi P, Goodman SN, Ioannidis JPA. Raw data from clinical trials: within reach? Trends Pharmacol Sci. 2013;34(12):645-647.
5. Krumholz HM, Ross JS. A model for dissemination and independent analysis of industry data. JAMA. 2011;306(14):1593-1594.
6. Doshi P, Jefferson T, Del Mar C. The imperative to share clinical study reports: recommendations from the Tamiflu experience. PLoS Med. 2012;9(4):e1001201.
7. Paroxetine and pediatric and adolescent patients. 2012. http://www.gsk.com/media/paroxetine.htm.
8. Berman F, Cerf V. Science priorities: who will pay for public access to research data? Science. 2013;341(6146):616-617.
9. Monforton C.Weight of the evidence or wait for the evidence? protecting underground miners from diesel particulate matter. Am J Public Health. 2006;96(2):271-276.
10. Koch HJ, Raschka C. Anthropometric data and acetylsalicylic acid pharmacokinetics. Int J Clin Pharmacol Ther. 2002;40(1):30-34.
11. Teschan PE, Beck GJ, Dwyer JT, et al. Effect of a ketoacid-aminoacid-supplemented very low protein diet on the progression of advanced renal disease: a reanalysis of the MDRD feasibility study. Clin Nephrol. 1998;50(5):273-283.
12. Gallo C, De Maio E, Di Maio M, et al CLIP (Cancer of the Liver Italian Programme) Investigators. Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma. BMC Cancer. 2006;6:196.
13. Huff JC, Drucker JL, Clemmer A, et al. Effect of oral acyclovir on pain resolution in herpes zoster: a reanalysis. J Med Virol. 1993;(suppl 1):93-96.
14. Holly JM, Goodwin FJ, Evans SJ, VandenBurg MJ, Ledingham JM. Re-analysis of data in two Lancet papers on the effect of dietary sodium and potassium on blood pressure. Lancet. 1981;2(8260-61):1384-1387.
15. Amer-Wa˚hlin I, Kjellmer I, Maršál K, Olofsson P, Rosén KG. Swedish randomized controlled trial of cardiotocography only versus cardiotocography plus ST analysis of fetal electrocardiogram revisited: analysis of data according to standard versus modified intention-to-treat principle. Acta Obstet Gynecol Scand. 2011;90(9):990-996.
16. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN; DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited. Diabetes. 2008;57(4):995-1001.
17. Brooks JO III, Yesavage JA, Carta A, Bravi D. Acetyl L-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach. Int Psychogeriatr. 1998;10(2):193-203.
18. Paradis NA, Young G, Lemeshow S, Brewer JE, Halperin HR. Inhomogeneity and temporal effects in AutoPulse Assisted Prehospital International Resuscitation - an exception from consent trial terminated early. Am J Emerg Med. 2010;28(4):391-398.
19. van der Linden YM, Lok JJ, Steenland E, et al Dutch Bone Metastasis Study Group. Single fraction radiotherapy is efficacious: a further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment. Int J Radiat Oncol Biol Phys. 2004;59(2):528-537.
20. Kobashigawa JA, Tobis JM, Mentzer RM, et al. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial. Am J Transplant. 2006;6(5 pt 1):993-997.
21. Chmielewski L, Walters MD, Weber AM, Barber MD. Reanalysis of a randomized trial of 3 techniques of anterior colporrhaphy using clinically relevant definitions of success. Am J Obstet Gynecol. 2011;205(1):e1-e8.
22. Reiffel JA, Reiter MJ, Freedman RA, et al ESVEM Investigators. Influence of Holter monitor and electrophysiologic study methods and efficacy criteria on the outcome of patients with ventricular tachycardia and ventricular fibrillation in the ESVEM trial. Prog Cardiovasc Dis. 1996;38(5):359-370.
23. Vansteenkiste J, Hedenus M, Gascon P, et al. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial. BMC Cancer. 2009;9:311.
24. Colquhoun D. Re-analysis of clinical trial of homoeopathic treatment in fibrositis. Lancet. 1990;336(8712):441-442.
25. Nagakane Y, Christensen S, Brekenfeld C, et al EPITHET Investigators. EPITHET: positive result after reanalysis using baseline diffusion-weighted imaging/perfusion-weighted imaging co-registration. Stroke. 2011;42(1):59-64.
26. Welling DB, Nagaraja HN. Endolymphatic mastoid shunt: a reevaluation of efficacy. Otolaryngol Head Neck Surg. 2000;122(3):340-345.
27. Johnston DL, Manyari DE, Kostuk WJ. The influence of intrinsic sympathomimetic activity on regional left ventricular function:; use of regional ejection fraction to demonstrate a beneficial action by pindolol over propranolol on hypokinetic segments. Can J Cardiol. 1985;1(3):174-179.
28. Thomsen BL, Sørensen TI. Analysis of the treatment effect on recurrent bleeding and death in patients with cirrhosis and esophageal varices: multistage competing-risks model compared to conventional methods:. Tthe Copenhagen Esophageal Varices Sclerotherapy Project. J Hepatol. 1998;28(1):107-114.
29. Johnson SR, Feldman BM, Pope JE, Tomlinson GA. Shifting our thinking about uncommon disease trials: the case ofmethotrexate in scleroderma. J Rheumatol. 2009;36(2):323-329.
30. McCann DJ, Li S-H. A novel, nonbinary evaluation of success and failure reveals bupropion efficacy versus methamphetamine dependence: reanalysis of a multisite trial. CNS Neurosci Ther. 2012;18(5):414-418.
31. Rothwell PM, Gutnikov SA, Warlow CP; European Carotid Surgery Trialist's Collaboration. Reanalysis of the final results of the European Carotid Surgery Trial. Stroke. 2003;34(2):514-523.
32. Diener HC, Rahlfs VW, Danesch U. The first placebo-controlled trial of a special butterbur root extract for the prevention ofmigraine: reanalysis of efficacy criteria. Eur Neurol. 2004;51(2):89-97.
33. Witkiewitz K, van der Maas HLJ, Hufford MR, Marlatt GA. Nonnormality and divergence in posttreatment alcohol use: reexamining the Project MATCH data "another way." J Abnorm Psychol. 2007;116(2):378-394.
34. Doshi P, Vedula SS, Li T. YODA and truth seeking in medicine. BMJ. 2013;347:f4251.
35. Ross JS, Lehman R, Gross CP. The importance of clinical trial data sharing: toward more open science. Circ Cardiovasc Qual Outcomes. 2012;5(2):238-240.
36. Ioannidis JP, Khoury MJ. Improving validation practices in "omics" research. Science. 2011;334(6060):1230-1232.
37. Holdren JP. Public access memorandum from the Office of Science and Technology Policy 2013. http://www.whitehouse.gov/sites/default/files/microsites/ostp/ostp-public-access-memo-2013.pdf.
38. Blumenthal D, Campbell EG, Anderson MS, Causino N, Louis KS. Withholding research results in academic life science: evidence from a national survey of faculty. JAMA. 1997;277(15):1224-1228.
39. Campbell EG, Clarridge BR, Gokhale M, et al. Data withholding in academic genetics: evidence from a national survey. JAMA. 2002;287(4):473-480.
40. Blumenthal D, Campbell EG, Gokhale M, et al. Data withholding in genetics and the other life sciences: prevalences and predictors. Acad Med. 2006;81(2):137-145.
41. Shlay JC, Chaloner K, Max MB, et al Terry Beirn Community Programs for Clinical Research on AIDS. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. JAMA. 1998;280(18):1590-1595.
42. Shiflett SC, Schwartz GE. Effects of acupuncture in reducing attrition and mortality in HIV-infected men with peripheral neuropathy. Explore (NY). 2011;7(3):148-154.
43. Christakis DA, Zimmerman FJ. Rethinking reanalysis. JAMA . 2013;310(23):2499-2500.
44. Simmonds MC, Brown JV, Heirs MK, et al. Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data. Ann Intern Med. 2013;158(12):877-889.